as 12-11-2024 4:00pm EST
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
Founded: | 2012 | Country: | United States |
Employees: | N/A | City: | NEW YORK |
Market Cap: | 4.2M | IPO Year: | N/A |
Target Price: | $14.00 | AVG Volume (30 days): | 17.3K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -8.26 | EPS Growth: | N/A |
52 Week Low/High: | $2.32 - $8.78 | Next Earning Date: | 11-12-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
SNPX Breaking Stock News: Dive into SNPX Ticker-Specific Updates for Smart Investing
PR Newswire
3 months ago
PR Newswire
5 months ago
PR Newswire
6 months ago
Newsfile
6 months ago
CNW Group
6 months ago
GlobeNewswire
6 months ago
GlobeNewswire
6 months ago
GlobeNewswire
6 months ago
The information presented on this page, "SNPX Synaptogenix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.